Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO) and Ramsay Health Care (OtherRMSYF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Rad Laboratories (BIO – Research Report) and Ramsay Health Care (RMSYF – Research Report).
Confident Investing Starts Here:
Bio-Rad Laboratories (BIO)
RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories on June 5 and set a price target of $381.00. The company's shares closed last Monday at $225.56.
According to TipRanks.com, McNamara 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, SOPHiA GENETICS, and Exact Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Rad Laboratories with a $316.40 average price target.
In a report released today, Steven Wheen from Jarden maintained a Hold rating on Ramsay Health Care, with a price target of A$44.05. The company's shares closed last Thursday at $24.00.
According to TipRanks.com, Wheen is ranked #1103 out of 9627 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Ramsay Health Care with a $25.09 average price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Analysts Offer Insights on Industrial Goods Companies: Boeing (BA) and Symbotic (SYM)
Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Boeing (BA – Research Report) and Symbotic (SYM – Research Report). Confident Investing Starts Here: Boeing (BA) In a report released today, Gavin Parsons from UBS maintained a Buy rating on Boeing, with a price target of $245.00. The company's shares closed last Tuesday at $215.73. According to Parsons is a 4-star analyst with an average return of 6.6% and a 66.3% success rate. Parsons covers the Industrial Goods sector, focusing on stocks such as L3Harris Technologies, StandardAero, Inc., and Northrop Grumman. Boeing has an analyst consensus of Strong Buy, with a price target consensus of $219.95, a 1.1% upside from current levels. In a report issued on June 4, Jefferies also maintained a Buy rating on the stock with a $250.00 price target. Craig-Hallum analyst Greg Palm assigned a Hold rating to Symbotic today. The company's shares closed last Tuesday at $28.23. Symbotic has an analyst consensus of Moderate Buy, with a price target consensus of $29.63.
Yahoo
9 hours ago
- Yahoo
TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts
Life sciences company Bio-Techne (NASDAQ:TECH) met Wall Street's revenue expectations in Q1 CY2025, with sales up 4.2% year on year to $316.2 million. Its non-GAAP profit of $0.56 per share was 10.4% above analysts' consensus estimates. Is now the time to buy TECH? Find out in our full research report (it's free). Revenue: $316.2 million vs analyst estimates of $317.4 million (4.2% year-on-year growth, in line) Adjusted EPS: $0.56 vs analyst estimates of $0.51 (10.4% beat) Adjusted EBITDA: $119.1 million vs analyst estimates of $114.1 million (37.7% margin, 4.3% beat) Operating Margin: 12.2%, down from 22.1% in the same quarter last year Organic Revenue rose 5.7% year on year (2.3% in the same quarter last year) Market Capitalization: $7.82 billion Bio-Techne's first quarter results were shaped by growth in its Protein Sciences division and ongoing cost management initiatives. CEO Kim Kelderman cited strong demand from large pharmaceutical customers and volume leverage in protein analysis tools as primary contributors to organic revenue growth. Management also emphasized operational efficiencies, such as streamlined SG&A and selective R&D investment, which supported profitability amid a challenging environment. CFO Jim Hippel noted, 'The teams have been doing a great job actually for a couple of years with the increased uncertainty that we've been seeing in our end markets.' Segment performance was mixed, with robust double-digit growth in large pharma offsetting flat results in U.S. academia due to funding uncertainty. Looking forward, Bio-Techne's outlook is influenced by several macroeconomic and policy-related uncertainties, particularly around U.S. National Institutes of Health (NIH) funding and evolving global tariffs. Management expects these headwinds to slow short-term growth, with CFO Jim Hippel acknowledging that 'the additional macro uncertainties around tariffs and potential budget likely to cause further distraction for our customers.' Despite this, the company believes it can mitigate most tariff impacts through regional production adjustments and supply chain optimization. CEO Kim Kelderman stated that clarity on NIH and tariff policies in the coming months should allow Bio-Techne to resume its growth trajectory, especially as funding priorities shift toward chronic disease research, which aligns with the company's core product strengths. Management attributed first quarter performance to growth in pharma end markets, efficiency initiatives, and strategic responses to external policy shifts. Forward-looking commentary centered on navigating NIH funding uncertainty and tariff impacts. Large pharma demand strong: Growth in the Protein Sciences division was driven by increased orders from large pharmaceutical companies, which saw double-digit organic growth. Management highlighted momentum in protein analysis tools, particularly the Maurice platform, for quality control and gene therapy applications. Academic market headwinds: U.S. academic revenue was flat as customers faced uncertainty around NIH funding, largely due to a proposed cap on indirect cost reimbursement and potential federal budget cuts. Management said this uncertainty impacted capital equipment purchases and order timing. Tariff mitigation strategies: Management explained that recent tariff escalations, especially those affecting China, had a limited impact due to Bio-Techne's global manufacturing footprint. The company mobilized teams to shift instrument production regionally and leverage supply chain flexibility, aiming to fully offset tariff costs by the next quarter. Diagnostics and Spatial Biology segment mixed: The diagnostics business experienced order timing effects, while the Asuragen portfolio maintained year-to-date double-digit growth. The COMET spatial biology platform delivered double-digit instrument growth, with adoption supported by multiomic automation capabilities. Cost discipline and operational leverage: CFO Jim Hippel described disciplined cost control, particularly in discretionary spending, as a meaningful contributor to margin performance. Efficiency gains from integrating acquisitions and digital process improvements were cited as supporting profitability during the quarter. Management projects that ongoing policy uncertainty and macroeconomic factors will influence growth and profitability in the near term, while strategic actions aim to mitigate these risks. NIH funding visibility critical: The company's academic end-market performance depends on clarity around future NIH budgets and grant priorities. Management noted that, while a severe funding reduction would have a limited long-term impact due to portfolio diversification, short-term uncertainty is dampening capital spending in U.S. academia. Tariff adaptation measures: Bio-Techne expects to fully neutralize current tariff impacts through regionalized production and supply chain adjustments by the start of the next quarter. These efforts are designed to protect margins even if trade policies evolve further. Pharma and biotech order patterns: Large pharma customers are expected to remain resilient, but smaller biotech spending is sensitive to capital markets and economic volatility. Management will watch for stabilization in China and continued adoption of GMP reagents and the Maurice platform to support recovery. In the coming quarters, the StockStory team will be monitoring (1) stabilization in U.S. academic and government funding, particularly any developments in NIH grant policies; (2) the effectiveness of Bio-Techne's tariff mitigation strategies and their impact on margins; and (3) growth trends in China and biotech end markets as local economic conditions and capital flows evolve. Execution in these areas will signal the company's ability to navigate ongoing macroeconomic and policy volatility. Bio-Techne currently trades at a forward P/E ratio of 23.9×. At this valuation, is it a buy or sell post earnings? Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
MAIA Biotechnology to Present at BIO International Convention 2025
CHICAGO, June 10, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its participation in the upcoming BIO (Biotechnology Innovation Organization) International Convention 2025 taking place June 16-19, 2025, in Boston, Massachusetts. MAIA Chairman and CEO Vlad Vitoc, MD, MBA will deliver a presentation featuring the latest findings from the Company's THIO-101 Phase 2 clinical trial evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC). Ateganosine is a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses. THIO-101 is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment. MAIA recently announced the design for the expansion of the THIO-101 trial, which will further assess the efficacy of treatment in third-line NSCLC patients. Presentation DetailsSession date and time: June 18 at 11:30 AM EDTPresenter: Vlad Vitoc, MD, MBA Registered participants may request a meeting with MAIA management via the BIO Partnering™ platform on the BIO 2025 website. About BIO BIO (Biotechnology Innovation Organization) is the world's largest advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About THIO-101, a Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using overall response rate (ORR) as the primary clinical endpoint. The expansion of the study will assess ORR in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has been generally well-tolerated to date in a heavily pre-treated population. For more information on this Phase 2 trial, please visit using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, "MAIA," "Company," "we," "our," and "us" refers to MAIA Biotechnology, Inc. and its subsidiaries. View source version on Contacts Investor Relations Contact +1 (872) 270-3518ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
